Skip to main content
. 2022 May 10;20:160. doi: 10.1186/s12916-022-02362-9

Fig. 4.

Fig. 4

Evaluation of clinical outcomes of patients who received matched targeted therapies. A Evaluation of the clinical outcomes of patients with exonic-breakpoint fusions detected by DNA NGS but not by RNA NGS and IHC. B Survival curves for exonic-breakpoint and intronic-breakpoint ALK fusions among patients with RNA NGS/IHC-validated ALK fusions